STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- Third
Quarter
- Revenue increased by 26.7% to €212.1m (€167.4m). Organic
revenue grew by 17.4%.
- Operating profit (EBIT) increased by 66.7% to €14.3m (€8.6m),
representing an operating margin of 6.7% (5.1%).
- Net profit amounted to €6.3m (€6.7m), which represents a net
profit margin of 3.0% (4.0%).
- EBITDA increased by 41.5% to €32.5m (€23.0m), corresponding to
an EBITDA margin of 15.3% (13.7%).
- EBITDAaL increased by 50.1% to €22.3m (€14.9m), corresponding
to an EBITDAaL margin of 10.5% (8.9%).
- Net cash flow from operating activities was €22.6m
(€29.4m).
- Basic/diluted earnings per share were €0.043 (€0.045).
Nine Months
- Revenue increased by 25.3% to €614.7m (€490.4m). Organic
revenue grew by 15.1%.
- Operating profit (EBIT) increased by 41.9% to €35.7m (€25.1m),
representing an operating margin of 5.8% (5.1%).
- Net profit amounted to €18.1m (€20.7m), which represents a net
profit margin of 2.9% (4.2%) affected by lower other
income/costs.
- EBITDA increased by 31.4% to €87.3m (€66.4m), corresponding to
an EBITDA margin of 14.2% (13.5%), impacted by €2.0m (€0.9m) merger
and acquisition related costs expensed.
- EBITDAaL increased by 36.7% to €58.3m (€42.6m), corresponding
to an EBITDAaL margin of 9.5% (8.7%).
- Net cash flow from operating activities amounted to €62.4m
(€57.8m).
- Basic/diluted earnings per share were €0.120 (€0.145).
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q3
2019
|
Q3
2018
|
Growth
|
9M
2019
|
9M
2018
|
Growth
|
FY
2018
|
|
Revenue
|
212.1
|
167.4
|
27%
|
614.7
|
490.4
|
25%
|
671.6
|
|
Operating
profit
|
14.3
|
8.6
|
67%
|
35.7
|
25.1
|
42%
|
33.7
|
|
Operating profit
margin, %
|
6.7%
|
5.1%
|
|
5.8%
|
5.1%
|
|
5.0%
|
|
Net profit
|
6.3
|
6.7
|
-4%
|
18.1
|
20.7
|
-13%
|
24.2
|
|
Net profit margin,
%
|
3.0%
|
4.0%
|
|
2.9%
|
4.2%
|
|
3.6%
|
|
Basic/diluted
earnings per share, €
|
0.043
|
0.045
|
-4%
|
0.120
|
0.145
|
-17%
|
0.167
|
|
|
|
|
|
|
|
|
|
EBITDA
|
32.5
|
23.0
|
41%
|
87.3
|
66.4
|
31%
|
90.7
|
|
EBITDA margin,
%
|
15.3%
|
13.7%
|
|
14.2%
|
13.5%
|
|
13.5%
|
|
EBITDAaL
|
22.3
|
14.9
|
50%
|
58.3
|
42.6
|
37%
|
58.5
|
|
EBITDAaL margin,
%
|
10.5%
|
8.9%
|
|
9.5%
|
8.7%
|
|
8.7%
|
|
EBITA
|
15.7
|
9.4
|
67%
|
39.8
|
27.0
|
47%
|
37.0
|
|
EBITA margin,
%
|
7.4%
|
5.6%
|
|
6.5%
|
5.5%
|
|
5.5%
|
For definition and reconciliation of alternative performance
measures, refer to note 11. As from Q3 2019 margins (including
margins of comparative figures) and growth rates have been
calculated based on EUR whole figures instead of figures rounded in
millions.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CET) on
6 November 2019. This interim report
and other information about Medicover is available at
medicover.com.
For further information, please contact:
Hanna Bjellquist
Head of Investor Relations
Phone: +46-70-303-32-72
E-mail: hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and
diagnostic services company and was founded in 1995. Medicover
operates a large number of ambulatory clinics, hospitals,
specialty-care facilities and laboratories and the largest markets
are Poland and Germany. In 2018, Medicover had revenue around
€672 million and 20,970 employees. For more information, go to
www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/interim-report-july-september-2019,c2954677
The following files are available for download:
|
https://mb.cision.com/Main/15662/2954677/1136318.pdf
|
Interim report
July-September 2019
|
